150 related articles for article (PubMed ID: 35815118)
1. Impact of the Pilot Volume-Based Drug Purchasing Policy in China: Interrupted Time-Series Analysis with Controls.
Chen Y; Ji X; Xiao H; Unger JM; Cai Y; Mao Z; Yeung K
Front Pharmacol; 2021; 12():804237. PubMed ID: 35815118
[TBL] [Abstract][Full Text] [Related]
2. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
3. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
[TBL] [Abstract][Full Text] [Related]
4. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
Zhao B; Wu J
Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
[TBL] [Abstract][Full Text] [Related]
5. "4+7" city drug volume-based purchasing and using pilot program in China and its impact.
Tang M; He J; Chen M; Cong L; Xu Y; Yang Y; Hou Z; Song P; Jin C
Drug Discov Ther; 2019; 13(6):365-369. PubMed ID: 31956236
[TBL] [Abstract][Full Text] [Related]
6. The impact of National Centralised Drug Procurement policy on the use of policy-related original and generic drugs in China.
Yang Y; Hu R; Geng X; Mao L; Wen X; Wang Z; Hao S; Cui D; Mao Z
Int J Health Plann Manage; 2022 May; 37(3):1650-1662. PubMed ID: 35132676
[TBL] [Abstract][Full Text] [Related]
7. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
Yang Y; Chen L; Ke X; Mao Z; Zheng B
BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
[TBL] [Abstract][Full Text] [Related]
8. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
Long H; Yang Y; Geng X; Mao Z; Mao Z
Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
[No Abstract] [Full Text] [Related]
9. Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.
Shang L; Cheng Y; Zhou J; Bao Y; Kong D; Huang R; Chen Y; Wang H; Gu N; Ma A
Front Pharmacol; 2024; 15():1302154. PubMed ID: 38389928
[No Abstract] [Full Text] [Related]
10. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
Lan T; Guan L; Pang X; Li X; Yu Q
J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
[TBL] [Abstract][Full Text] [Related]
11. The change of drug utilization in China's public healthcare institutions under the "4 + 7" centralized drug procurement policy: Evidence from a natural experiment in China.
Lu J; Long H; Shen Y; Wang J; Geng X; Yang Y; Mao Z; Li J
Front Pharmacol; 2022; 13():923209. PubMed ID: 36081942
[No Abstract] [Full Text] [Related]
12. A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China.
Wen X; Xu L; Chen X; Wu R; Luo J; Wan Y; Mao Z
Front Pharmacol; 2023; 14():984794. PubMed ID: 37731741
[No Abstract] [Full Text] [Related]
13. Influence of Chinese National Centralized Drug Procurement on the price of policy-related drugs: an interrupted time series analysis.
Wang N; Yang Y; Xu L; Mao Z; Cui D
BMC Public Health; 2021 Oct; 21(1):1883. PubMed ID: 34663282
[TBL] [Abstract][Full Text] [Related]
14. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.
Acosta A; Ciapponi A; Aaserud M; Vietto V; Austvoll-Dahlgren A; Kösters JP; Vacca C; Machado M; Diaz Ayala DH; Oxman AD
Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD005979. PubMed ID: 25318966
[TBL] [Abstract][Full Text] [Related]
15. Impacts of the zero mark-up drug policy on hospitalization expenses of COPD inpatients in Sichuan province, western China: an interrupted time series analysis.
Wang J; Li P; Wen J
BMC Health Serv Res; 2020 Jun; 20(1):519. PubMed ID: 32513170
[TBL] [Abstract][Full Text] [Related]
16. The impacts of the "4+7" pilot policy on the volume, expenditures, and daily cost of Serotonin-Specific Reuptake Inhibitors (SSRIs) antidepressants: A quasi-experimental study.
Wen X; Wang Z; Xu L; Luo J; Geng X; Chen X; Yang Y; Cui D; Mao Z
Front Pharmacol; 2022; 13():829660. PubMed ID: 36060003
[No Abstract] [Full Text] [Related]
17. Trends in accessibility of negotiated targeted anti-cancer medicines in Nanjing, China: An interrupted time series analysis.
Liu Y; Yi H; Fang K; Bao Y; Li X
Front Public Health; 2022; 10():942638. PubMed ID: 35937254
[TBL] [Abstract][Full Text] [Related]
18. Influence of Government Price Regulation on the Price, Volume and Spending of Antibiotics in China: A Controlled Interrupted Time Series Study.
Wushouer H; Luo Z; Guan X; Shi L
Int J Health Policy Manag; 2022 Feb; 11(2):218-223. PubMed ID: 32702801
[TBL] [Abstract][Full Text] [Related]
19. Medicaid prescription limits: policy trends and comparative impact on utilization.
Lieberman DA; Polinski JM; Choudhry NK; Avorn J; Fischer MA
BMC Health Serv Res; 2016 Jan; 16():15. PubMed ID: 26772962
[TBL] [Abstract][Full Text] [Related]
20. One-year assessment of joint procurement of pharmaceuticals in the public health sector in Jordan.
Al-Abbadi I; Qawwas A; Jaafreh M; Abosamen T; Saket M
Clin Ther; 2009 Jun; 31(6):1335-44. PubMed ID: 19695398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
